Short Interest in Cellectis S.A. (NASDAQ:CLLS) Expands By 59.7%

Cellectis S.A. (NASDAQ:CLLS) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totaling 285,600 shares, agrowthof59.7% from the July 31st total of 178,800 shares. Based on an average trading volume of 152,400 shares, the short-interest ratio is currently 1.9 days. Based on an average trading volume of 152,400 shares, the short-interest ratio is currently 1.9 days.

Hedge Funds Weigh In On Cellectis

A number of large investors have recently made changes to their positions in CLLS. Wells Fargo & Company MN increased its holdings in shares of Cellectis by 103.4% in the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 12,500 shares during the period. Millennium Management LLC acquired a new position in shares of Cellectis in the 4th quarter valued at about $962,000. OLD Mission Capital LLC acquired a new position in shares of Cellectis in the 1st quarter valued at about $31,000. Long Focus Capital Management LLC increased its holdings in shares of Cellectis by 2.2% in the 1st quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company’s stock valued at $5,849,000 after purchasing an additional 100,000 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Cellectis by 228.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock valued at $5,856,000 after purchasing an additional 3,284,409 shares during the period. Institutional investors and hedge funds own 63.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CLLS. Barclays reduced their price objective on shares of Cellectis from $5.00 to $4.00 and set an “overweight” rating for the company in a report on Tuesday, May 13th. Wall Street Zen downgraded shares of Cellectis from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Cellectis has an average rating of “Buy” and a consensus price target of $4.00.

Cellectis Price Performance

Shares of NASDAQ CLLS opened at $2.68 on Friday. Cellectis has a twelve month low of $1.10 and a twelve month high of $3.24. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $148.95 million, a price-to-earnings ratio of -3.27 and a beta of 3.03. The firm has a 50-day moving average of $2.36 and a two-hundred day moving average of $1.73.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Monday, August 4th. The biotechnology company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.09). Cellectis had a negative net margin of 100.69% and a negative return on equity of 68.05%. The firm had revenue of $18.19 million for the quarter, compared to analysts’ expectations of $10.07 million. As a group, analysts expect that Cellectis will post -0.46 earnings per share for the current fiscal year.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.